ODF2L and neoplasm: Treatment with siODF2L-LNPs successfully decreased ODF2L expression in ID8 tumors but not in the main organs, including the heart, liver, spleen, lung, and liver (Figure 7F and Supplemental Figure 8B), resulting in both the substantial activation of CDK1 (Figure 7F) and exacerbation of DNA damage (Figure 7G) in the tumor cells when combined with AZD1775.